Michael Scott(CLXXII)
Michael is a biotechnology leader who has been developing novel cellular medicines since 2011. He has led teams responsible for developing medical devices, cell therapy combination products and clinical procedures resulting in clinical trials to treat type one diabetes (while at ViaCyte, now Vertex) and Parkinson's disease (at BlueRock Therapeutics, now Bayer). Prior to working on cellular medicines, Michael developed medical devices to treat heart disease.
Born and raised in London, Ontario, Canada, he earned engineering degrees at the University of Waterloo followed by a Ph.D. in Medical Biophysics at the University of Western Ontario, Robarts Research Institute and Cleveland Clinic Foundation.
A dual Canadian and US citizen, Michael resides in the San Francisco Bay area developing cellular medicines to treat heart failure, type one diabetes and Parkinson's disease at Novo Nordisk.